New registry aims to unlock TAVR benefits in complex heart valve disease
NCT ID NCT06589063
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This registry is tracking 1,350 people with severe low flow, low gradient aortic stenosis who are getting a TAVR procedure. Researchers are collecting data on risks, complications, and survival for up to 5 years. The goal is to better understand who does well with this treatment and why.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcatheter aortic valve replacement (TAVR)
- What this could lead to
- If successful, this registry could clarify which patients with this specific type of aortic stenosis benefit most from TAVR, improving treatment decisions.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,350 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2024
- Expected to finish
-
Dec 2037
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with severe low flow, low gradient aortic stenosis (LFLG-AS) undergoing transcatheter aortic valve replacement (TAVR)
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * LFLG-AS diagnosis according to current European Society of Cardiology guidelines * Age 18 years or older * Written informed consent Exclusion Criteria: * LFLG-AS pseudo-severe or non-confirmed severe aortic stenosis * LFLG-AS referred for medical treatment or undergoing surgery
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Low flow, low gradient aortic stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Salerno
RECRUITINGSalerno, 84131, Italy